Matthew Gline
CEO, Director, Roivant Sciences
Bought, 12 months
$0.0M
Sold, 12 months
$46.2M
Companies
1
Latest trade
Apr 16, 2026
Companies
Roivant SciencesCEO, Director −$46.2M
Trades
Open-market trades from SEC Form 4 only: no grants, option exercises or gifts. People are matched by the name on their filings, so two people with the same name share this page. For information only — not investment advice.